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Abstract
Novel Coronavirus (COVID-19) is a new strain of coronavirus that may cause
illness in animals or humans. SARS-CoV-2 was first identified in late December
2019, in Wuhan, China. The coronavirus infected patients ‘who suffering from
Immundeficient or chronic inflammation are at higher risk of getting a severe
infection from COVID-19. The symptoms such as proinflammatory and
hypercoagulable, non-cardiac pneumonia, multi-organ failure, and ARDS
resulting in sudden death have been seen in those patients. Supportive treatment
is still the main strategy in treating this disease since there is no evidence that
current medicine can prevent or cure the infection resulting from coronavirus.
However, more investigations are needed to illustrate their biochemical and
hematological

disorders,

complications,

prevention,

and

treatments.

In

conclusion, this review provides the most recent information on the current
global pandemic coronavirus infection (COVID-19), which may help the health
workers and researchers to pursue their studies.
Keywords: SARS-CoV-2, COVID-19, Pneumonia, Coronavirus, Treatment,
Prevention
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ّ
الملخـص:
فيروس كورونا المستجد ) (COVID-19هو ساللة جديدة من الفيروسات التاجـية التي قد تُسبب المرض
في الحيوانات أو البشر .تـم تحديد ) (SARS-CoV-2ألول مرة في أواخر ديسمبر  .0102وتجدر
اإلشارة إلى أن المرضى الذين يعانون من نقص المناعة،أو االلتهاب المزمن هم أألكثر عرضةً لإلصابة
الشديدة بهذا الفيروس  .COVID-19وعادة ما تظهر عليهم أعراض مثل ) ، (Pro-inflammatoryو
هي أعـراضُ تفاقم االلتهاب ،وفرط في تخثر الدم ،والتهاب رئوي غير قلبي ال َمنشأ ،و فشل متعدد
األعـضاء ،و )) ARDSومتالزمة الفشل التنفسي الحاد ،مما يؤدي إلى الموت المفاجئ .تُــعــد التدابير
الوقائية هي اإلستراتيجية الرئيسية لمنع انتشار هذا الفيروس؛ حيث ال يوجد ـ في الوقت الحالي ـ دليل طبي
لمنع العدوى الناتجة عن فيروس كورونا أو معالجتها؛ لذلك ،ثَــمــةً حاجة إلى مزيد من البحوث والدراسات
لفهم آلية االضطرابات الكيميائية الحيوية والدموية الناجمة عن اإلصابة بهذا الفيروس ،ومضاعفاته
والوقاية منه وكيفية عالجه .وفي الختام ،تُـقـدم وتُـوفـر هذه المراجعة أحدث المعلومات والبيانات المنشوره
حول هذا الفيروس الوبائي ) ، (COVID-19والتي قد تساعد العاملين في المجال الصحي والباحثين على
متابعة دراساتهم وأبحاثهم لتحقيق األهداف المرجـوة.
الكلمات المفتاحية :الفيروسات التاجـية ،فيروس كوروونا المستجد ،الوقاية  ،العالج

Introduction
By the end of 2019, several patients were diagnosed with pneumonia of unknown
reasons, epidemiologically associated with the same seafood market in Wuhan,
Hubei province, central China. This condition caught the attention of the Chinese
Center for Disease Control and Prevention (CDC), and the WHO launched an
emergency response immediately, and later the CDC experts identified that the
pneumonia was caused by a novel coronavirus (NCV). The Chinese government
had taken great and extraordinary measures to control the outbreak. On January
30, 2020, the World Health Organization (WHO) designated an outbreak of a
novel coronavirus not seen before in humans to be a “public health emergency of
international concern” (PHEIC); this was followed by the declaration of a
pandemic on March 11, 2020 (WHO, 2020c, Lai et al., 2020).
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The novel virus was named Wuhan coronavirus or 2019 novel coronavirus
(2019-nCov) by the Chinese researchers. The International Committee on
Taxonomy of Viruses (ICTV) named the virus as SARS-CoV-2 and the disease
as COVID-19. WHO officially named the disease COVID-19. By May 28th,
2020, the pandemic cases were 5,868,922 and 360,476 deaths worldwide with a
6.14% mortality rate estimated by WHO on May 28th, 2020. In Palestine, the
pandemic confirmed cases were 570 with 4 deaths only. The diseases spread
extremely very fast as by the end of June within only one month, the cases have
been nearly doubled as the coronavirus cases by this time were 10,286,435,
deaths 505,252 (8%), and recovered were 5,583,314. The high incidence rate and
cases were in the USA (2,638,386), then Brazil (1,345,470), Russia (641,156),
India, UK, Spain, Peru, Chile, Italy, and Iran respectively. In Palestine by this
time, at the end of June, the reported cases were increased very sharply by about
four times, more than 2,200 cases reported. The outbreak of the disease globally
was continued raising very sharp as by 11th July 2020, the coronaviruses cases
reported was 12,872,339 and the death cases were 568,312, the increase rate of
the new cases was ~8% and the rate of death increased by 1.125%; within about
two weeks period only, which considered high rates. The highest incidences by
this time in the USA was 3,356,242 reported cases, then Brazil (1,840,812), India
(854,480), Russia (727,162), and Peru (322,710), etc. as shown in Table-1. In
terms of the outbreak of the disease, the rank of the countries is changing every
day, but the USA and Brazil remain and still rank first and second respectively
for a while. In Palestine by 11th July 2020, the confirmed cases were 6688, and
the death cases were 36, with an increased rate of 304%, which extremely very
high and considered the highest worldwide. The highest cases were in Hebron
Governorate (4620 cases), with about 70% of the total reported cases, as shown
in the geographical location of confirmed cases (Figure 1). The high outbreak of
the disease in this region (Hebron Governorate), as 90% of infections have been
caused by people meeting up with their families or attending wedding parties or
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funerals and failing to follow health recommendations and maintain social
distancing according to the Palestinian Ministry of Health officials.
Figure 1 shown Coronavirus disease 2019 (COVID-19) occupied Palestinian
territory by 11th July 2020, Cumulative confirmed, recovered and death cases,
confirmed cases per day (from April to July 2020), confirmed cases by gender
(5th March to 11th July 2020), and confirmed cases by age in Palestine. Some data
reported

were

included

and

some

excluded

(http://www.emro.who.int/pse/palestine-news/top-story.html).

East

Jerusalem.

Table-1

shows

cases for the top 30 countries including, other information such as daily new
cases, total death, totally recovered, a total test of each country, etc. While the
actual and accurate causes and effective treatment of COVID-19 are still
unknown or unavailable and the number of active cases of the infection is rising
every day as mentioned, which raises panic and concern on public health
worldwide. Prevention is still the best strategy to face this pandemic. In this
review, we summarized the available up to date studies by global researchers
about COVID-19. Besides, we highlighted the virology, pathology and cell
targeting, genomic structure and variation, clinical manifestations, transmission,
epidemiology, ABO blood groups, and pregnancy-relation of COVID-19, animal
hosts, diagnosis, treatment, and prevention about this virus and the pandemic.
The disease spread extremely very fast as by 17th November, 2020 (11:15 GMT)
there were 55,446,791 cases diagnosed; with 4.3 times increase in 4 months only,
the recovered cases were 38,606,024, and the death cases were 1,334,297, with
an increase of ~2.35 times in 4 moths too. The highest incidences by this time
were in the USA with 11,538,280 (~3.44 times increase) reported cases, then
India (8,874,290, ~104 times increase, which is extremely very high), Brazil
(5,876,740), France (1,991,233), Russia (1,971,013), Spain (1,521,899), UK
(1,390,681), Argentina (1,318,384) and Italy (1,205,881). The rank of the
countries is changing every day, but the USA remain and still rank first for a
while. While Palestine on 16th November, 2020 (15 GMT) the confirmed cases
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were 76162, with ~11.4 times increase with in 4 months, which is extremely very
high. The death cases were 647, and recovered cases in Palestine were 66553
(~87.5%). With these confirmed cases Palestine ranked 69 among 215 countries
that have coronavirus. It is worth to mention that Palestine on 13th July 2020 and
1st July, ranked 85 and 97 respectively; among 215 countries that have
coronavirus; with one of the highest outbreak rate in the world; compare to
population number. Within only 4 months period the Palestine rank changed
from 97 to 69; however, if the outbreak in Palestine remains rising in the same
rate, Palestine after a short period will be one of the top countries having the
disease, if real and serious precautions did not apply especially the health
recommendations, isolation and maintain social distance. The high outbreak of
the disease in this region (Hebron Governorate) with 12277 confirmed cases
(~25%), as 90% of infections have been caused by people meeting up with their
families or attending wedding parties or funerals and failing to follow health
recommendations and maintain social distancing according to Palestinian
Ministry of Health officials. While the actual and accurate causes and effective
treatment of COVID-19 are still unknown or unavailable and the number of
active cases of the infection is rising every day as mentioned, which rising panic
and concern on public health worldwide. Prevention is still the best strategy to
face this pandemic. In addition, these numbers are possibly an underestimate of
the infected and dead due to limitations of surveillance and testing.
While the vaccines may potentially prevent infection, they cannot cure the
disease, but researchers worldwide are working around the clock to find a
vaccine against SARS-CoV-2. Vaccines typically require years of research and
testing before reaching the clinic, but scientists are racing to produce a safe and
effective coronavirus vaccine by next year. Researchers are testing 54 vaccines in
clinical trials on humans, and at least 87 preclinical vaccines are under active
investigation in animals. Work began in January with the deciphering of the
SARS-CoV-2 genome. The first vaccine safety trials in humans started in March,
and now 12 have reached the final stages of testing. Some of these trials will fail,
Published by Arab Journals Platform, 2020
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and others may end without a clear result. But a few vaccines may succeed in
stimulating the immune system to produce effective antibodies against the virus.
Moderna develops vaccines based on messenger RNA (mRNA) to produce viral
proteins in the body. They have yet to bring one to the market. In January, they
began developing a vaccine for the coronavirus. The vaccine contains genetic
instructions for building a coronavirus protein, known as spike. When injected
into cells, the vaccine causes them to make spike proteins, which then get
released into the body and provoke a response from the immune system. On
November 9, 2020 New York-based Pfizer and the German company BioNTech
made history by presenting preliminary data indicating that their coronavirus
vaccine was over 90 percent effective. It was the first time anyone had found
such evidence. A week later, Moderna reported similar findings with a similar
vaccine. On November 16, 2020 Moderna announced that a preliminary analysis
of the trial indicated that the vaccine was 94.5 percent effective. Out of 95
participants who got Covid-19, 90 had the placebo and only 5 had the vaccine.
The results came just a week after Pfizer made a similar announcement about
their own vaccine, which is also based on an mRNA molecule encoding the spike
protein. Another promising result from Moderna’s trial was the finding that the
vaccine appears to protect people from severe disease. Of the 11 volunteers who
developed severe disease, none were vaccinated. The trial will continue to gather
more results; Moderna says it plans to submit an application for an Emergency
Use Authorization in the next few weeks. There are different vaccines are under
testing by several companies worldwide, either they are in clinical trials or at
preclinical investigation as mentioned. (The New York times, 2020).
Methodology
Literature and guidelines in different databases were collected and summarized.
Preciously, a literature review using Google Scholar, Medline, PubMed, Web of
Science, and Science Direct was conducted to identify peer-reviewed published
articles on SARS-CoV, MERS-CoV, and 2019-nCoV. The initial terms “words”
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that match with the title or abstract or with the topic including 2019-nCoV, 2019
novel coronavirus, SARS, CoV-2, COVID-19, coronavirus disease 2019, NCP,
Novel coronavirus pneumonia were used in searching the databases. Further
search using the keywords mentioned above, SARS, SARS-CoV, severe acute
respiratory syndrome, MERS, MERS-CoV, Middle East respiratory syndrome, in
combinations of with "pike protein, genome, reproductive number, incubation
period, fatality rate, clinical characteristics, pathology, autopsy, treatment, and
prevention. Moreover, official documents that have been released by the World
Health Organization (WHO) were accessed for up to date data on COVID-19.
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Figure 1: Coronavirus disease 2019 in Palestine
(http://www.emro.who.int/pse/palestine-news/landing-page-for-covid19.html)

Table-1: Reported Cases and Deaths by Country
(https://www.worldometers.info/coronavirus/)
Country,
Other

Serious,
Critical

Total
Cases/
1M pop

Deaths
/1M pop

Total Tests

4,801,870
1,728,126

58,807
15,819

1,651
10,138

72.9
415

41,773,190

331,060,504

1,213,512
537,599
501,061
214,152
281,114
N/A
180,852
N/A
127,715

555,808
294,163
214,766
96,876
24,034
N/A
79,686
N/A
132,498

8,318
8,944
2,300
1,315
1,999
617
378
185
539

8,658
619
4,983
9,784
16,319
6,438
2,289
4,256
4,453

336
16
78
354
360
607
269
660
67

4,572,796
11,587,153
23,031,056
1,904,242
1,273,627
5,734,599
723,668
11,782,192
2,108,570

212,603,520
1,380,381,949
145,936,493
32,983,682
19,120,870
46,755,366
128,969,990
67,896,748
59,328,450

12,829
5,197
34,945
2,181

219,993
156,700
194,579
165,396

24,481
86,975
13,303
61,903

3,359
2,118
67
2,230

3,062
1,126
4,016
6,589

153
24
578
63

1,972,207
1,562,638
5,900,552
2,226,290

84,021,254
220,990,656
60,458,858
34,827,377

5,344
9,134
2,352
30,004
5,119
8,773
146
1,810
4,634
3,769
3,606
3,055
5,526
5,031
464
9,782

193,217
184,500
93,614
78,388
61,186
71,266
98,934
41,408
78,634
23,876
35,638
43,079
N/A
30,107
55,380
17,196

13,420
6,178
87,829
62,360
79,057
27,308
4,048
54,291
326
53,513
36,455
29,060
N/A
32,071
9,088
35,628

1,194
278
1
496
875
2,156
141
688
3
41

2,513
2,385
1,116
2,616
2,856
2,844
36,729
2,157
58
793
277
1,869
7,415
3,808
6,872
5,401

63
109
14
460
101
232
52
40
3
37
13
76
547
285
49
844

3,930,223
6,376,054
943,524
1,384,633
1,006,093
3,183,516
409,199
456,042
90,410,000
135,000
1,061,367
671,478
600,019
181,564
1,134,653
1,361,830

84,363,898
83,792,278
164,734,934
65,278,075
50,897,758
37,751,539
2,807,805
45,207,451
1,439,323,776
102,379,206
273,603,023
40,241,752
10,101,130
17,649,781
9,449,221
11,591,164

Total Cases

Total
Deaths

Total
Recovered

World
USA

12,872,339
3,356,242

568,312
137,414

7,502,157
1,490,702

Brazil
India
Russia
Peru
Chile
Spain
Mexico
UK
South
Africa
Iran
Pakistan
Italy
Saudi
Arabia
Turkey
Germany
Bangladesh
France
Colombia
Canada
Qatar
Argentina
China
Egypt
Indonesia
Iraq
Sweden
Ecuador
Belarus
Belgium

1,840,812
854,480
727,162
322,710
312,029
300,988
295,268
288,953
264,184

71,492
22,718
11,335
11,682
6,881
28,403
34,730
44,798
3,971

257,303
248,872
242,827
229,480
211,981
199,812
183,795
170,752
145,362
107,347
103,128
97,509
83,594
81,158
75,699
75,194
74,898
67,209
64,932
62,606

Active
Cases

400
85
308
89
32
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Result and Discussion
Virology
Coronaviruses (CoVs) are named for the crown-like spikes on their surface
protruding to the periphery with a diameter of 60-160nm under electron
microscopy (Shereen et al., 2020, Singhal, 2020, Chavez et al., 2020). They
belong to the Nidovirales order, which contains Coronaviridae, Arteriviridae, and
Roniviridae families (Xie and Chen, 2020, Kang et al., 2020). The Coronaviridae
is composed of a large, single, positive-sense RNA (+ssRNA) genome of 27-32
kb with a 5'-cap structure and 3'poly-A tail
which interacts with the nucleoprotein (Shereen et al., 2020, Kang et al., 2020).
The Coronavirinae is one of two subfamilies in the Coronaviridae family, and the
other one is the Torovirinae (Kang et al., 2020). The Coronairinae is further
subdivided into four groups, the alpha, beta, gamma, and delta coronaviruses.
The groups were labeled by
phylogenetic clustering (Shereen et al., 2020, Kang et al., 2020). Coronavirus is a
beta virus that infects vertebrates including humans and is known to cause
gastrointestinal (GI) and respiratory diseases and sometimes involving important
organs such as the liver, kidney, heart, and brain (Kang et al., 2020, Chavez et
al., 2020).
Before 2019 six CoVs only were identified to cause a human respiratory
infection; HKU1, HCoV-NL63, HCoV-OC43, and HCoV-229E only induce mild
upper respiratory disease or sometimes contributed to common clod (Kang et al.,
2020, Yang et al., 2020b), SARS-CoV (Severe Acute Respiratory Syndrome
Coronavirus) and MERS-CoV (the Middle East Respiratory Syndrome
Coronavirus) attack lower respiratory tract and always induce severe respiratory
syndrome (Kang et al., 2020). Genome sequence analysis shows that the 2019
novel coronavirus (2019-nCoV) has a typical beta coronavirus genome structure
that includes SARS-CoV and MERS-CoV, it is 82% identical to human SARS-
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CoV and 50% to MERS-CoV (Kang et al., 2020, Xie and Chen, 2020). See
figure 3. It has been the seventh member of coronaviruses that infect humans.
Moreover, phylogenetic analysis of the viral genome reveals that the coronavirus
is 89.1% (nucleotide similarity) identical to a group of bat SARS-like
coronaviruses bat-SL-CoVZXC21 (NCBI accession number MG772934) (Yang
et al., 2020b, Xie and Chen, 2020). Also, the genome sequence homology of
2019-nCoV and SARS is about 79%, the 2019-nCoV is closer to the SARS-like
bat CoVs bat-SL-CoVZC45 (NCBI accession number MG772933) than the
SARS-CoV by 96% (Wang et al., 2020b, Yang et al., 2020b).
The genome of coronaviruses is the largest among all RNA viruses; all
coronaviruses have similar organization and expression of the genome (Kang et
al., 2020, Shereen et al., 2020). 2019-nCoV has 14 open reading frames (ORFs)
that encode 27 proteins. ORF1ab and ORF1a are located at the 5' end, both
encode 15 non-structural proteins (nsps) from nsp1 to nsp10 and from nsp12 to
nsp16 respectively (Shereen et al., 2020, Kang et al., 2020, Yang et al., 2020b).
They are followed by four structural proteins, Nucleocapsid (N), Spike (S),
Envelope (E), and Membrane (M), which are encoded by four other ORFs at the
3’end (Kang et al., 2020) and eight accessory proteins (3a,3b,p6, 7a, 7b, 8b, 9b
and orf14) (Yang et al., 2020b) Figure 2 & Figure 3.
Pathology and Cell Targeting
The envelope of the virus includes three proteins: M protein binds nucleocapsids
and enhances viral assembly and budding, E protein is involved in viral
morphogenesis, release as well as pathogenesis, and S protein contributes to
homotrimer spikes which recognize the receptor of the cell, thus helping virus
invade target cell (Kang et al., 2020). See figure 1. They also express other
polyproteins, nucleoproteins, and membrane proteins, such as RNA polymerase,
3-chymotrypsin-like protease, papain-like protease, helicase, glycoprotein, and
accessory proteins (Shereen et al., 2020).

https://digitalcommons.aaru.edu.jo/hujr_a/vol9/iss1/4

10

hejaz et al.: A REVIEW ON CORONA VIRUS DISEASE (COVID-19)
Hejaz A Hatem, et al., A REVIEW ON CORONA VIRUS …., H.U.R.J, Vol. (9), 2020

55

Figure 2. The electron microscope image depicts the spikes on the outer surface
of the coronavirus-2 in addition to several protein particles. Eckert A, Higgins D,
Centers

for

Disease

Control

and

Prevention.

ID#

23313;

2020.

https://phil.cdc.gov/Details.aspx?pid=23313. Accessed April 6th, 2020. (Eckert
A, 2020).
The entry mechanism of a coronavirus depends upon cellular proteases which
include,

human

airway

trypsin-like

protease

(HAT),

cathepsins,

and

transmembrane protease serine 2 (TMPRSS2) that split the spike protein and
establish further penetration changes, it has been reported that the cellular
protease MPRSS2 blocks entry of the virus by cleaving the spike protein and
may constitute a treatment option (Hoffmann et al., 2020). SARS-CoV and
MERS-CoV recognize exopeptidases while other coronaviruses mostly recognize
aminopeptidases or carbohydrates as a key receptor for entry to human cells
(Bertram et al., 2011, Glowacka et al., 2011).
The spike S protein of 2019-nCov binds to angiotensin-converting enzyme 2
(ACE2) on target cells, which express ACE2 on their surface, the same
mechanism as SARS-CoV. See figure 2. In a recent fluorescent study, it was
confirmed that the 2019-nCoV also uses the same ACE2 cell receptor and
mechanism for the entry to host cell which is previously used by the SARS-CoV
(Xu et al., 2020, Gralinski and Menachery, 2020). Zhou et al. confirmed that
2019-nCoV binds to all ACE2 expressing cells except mice ACE2 cells (Zhou et
al., 2020).
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Whereas MERS-CoV uses dipeptidyl peptidase 4 (DPP4) as the primary receptor
(Xie and Chen, 2020, Wu et al., 2020a). 2019-nCoV binds ACE2 with above 10
folds higher affinity than SARS-CoV, but higher than the threshold required for
virus infection (Wrapp et al., 2020). Xu et al. concluded that despite the sequence
diversity between 2019-CoV and SARS-CoV, they share the same 3-D structure
in the Receptor Binding Domaine (RBD), thus they have similar van der Waals
and electrostatic properties in the interaction interface of human ACE2 receptors
(Xu et al., 2020).
The S protein at metastable prefusion conformation undergoes several structural
arrangements to combine with the viral membrane of host cells (Su et al., 2016,
Bosch et al., 2003). The S1 subunit binds to the cell receptor, triggers the
prefusion trimer's instability, and sheds the S1 subunit, this results in a highly
stable post-fusion conformation of the S2 subunit (Walls et al., 2017). The S1
subunit has two different states a “down” conformation and an “up”
conformation state, which corresponds to a receptor inaccessible state and an
unstable receptor-accessible state, respectively (Gui et al., 2017, Pallesen et al.,
2017, Walls et al., 2019) Figure 3.
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Figure 3. The life cycle of SARS-CoV 2. It starts by binding S protein to the
ACE2 receptor, changing the conformation of S protein facilitating the fusion of
viral envelope. Then SARS-CoV2 releases its RNA into the host cell, Genome
RNA is translated into viral replicase polyproteins pp1a and 1ab, which are then
cleaved into small products by viral proteinases. By discontinuous transcription,
the polymerase produces a series of sub-genomic mRNA which are translated
into viral proteins. Viral proteins and genome RNA are assembled into virions in
the ER and Golgi and then transported outside the cell via vesicles (Shereen et
al., 2020).
The respiratory system is the primary target of 2019-nCoV but bioinformatic
analysis of single-cell transcriptomes datasets of lung, esophagus, gastric, ileum,
and colon reveal that the digestive system is also a potential route of entry of
2019-nCoV as ACE2 is highly expressed in absorptive enterocytes from the
ileum and colon (Zhang et al., 2020).
The S protein has two regions the S1 and S2, the former has a stronger affinity
with the receptor binding RBD to bind ACE2 to enter the target cell, but since
there are changes in the residue in S1 and S2 there are differences in the binding
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process and the conformation between 2019-nCoV and SARS-CoV, thus
available monoclonal antibodies do not react with 2019-nCoV (Dong et al., 2020,
Ren et al., 2020, Wrapp et al., 2020).
The residues at positions 442, 472, 479, 487, and 491 in S-protein are reported to
be at receptor complex interface with ACE2, but only TYR491 out of the five are
preserved in 2019-nCoV (Xie and Chen, 2020). Arg426 is replaced by Asn426 in
2019-nCoV, so hydrogen bonds are lost which leads to the increased binding free
energy of 2019-nCoV compared to SARS-CoV (-50.6kcal mol–1 vs. -78.6kcal
mol–1) (Xu et al., 2020, Xie and Chen, 2020).
It is reported a furin-like cleavage site in the S-protein of 2019-nCoV, which is
absent in other beta-coronaviruses (Coutard et al., 2020, Wrapp et al., 2020).
Also, another research team discovered an “RRAR” furin recognition site by an
insertion in the S1/S2 protease cleavage site in 2019-nCoV, instead of a single
arginine compared to SARS-CoV (Xie and Chen, 2020, Wrapp et al., 2020).
Based on current data 2019-nCoV is likely to cause cell pyroptosis in
lymphocytes through the activation of NLRP3 inflammasome (Yang, 2020).
Pyroptosis is a novel inflammatory form of programmed cell death. In 2019, it
was found that SARS-CoV Viroporin 3a triggers the activation of the NLRP3
inflammasome and the secretion of IL-1β in bone marrow-derived macrophages,
suggesting SARS-CoV induced cell pyroptosis (Chen et al., 2019). Studies
reported that patients with 2019-nCoV have increased IL-1β in the serum (Huang
et al., 2020a). As the increase in IL-1β is an indicator of cell pyroptosis, it is
suggested that cell pyroptosis is the pathogenesis of 2019-nCoV. Both classical
and non-classical cell pyroptosis can induce an increase in IL-1β, so it is unclear
which pathway is involved in 2019-nCoV.
Genomic Structure and Variation
The genomic structure of CoVs is 5′-leader-UTR-replicase-S (Spike)–E
(Envelope)-M (Membrane)-N (Nucleocapsid)-3′UTRpoly (A) tail (Yang et al.,
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2020b). In GenBank, there is only one complete 2019-nCoV genome (29870-bp,
excluding the poly (A) tail) (accession number MN908947) (Phan, 2020). Five
typical ORFs on the same coding strand were identified, including ORF1ab
polyprotein (7096-aa), spike glycoprotein (1273-aa), an envelope protein (75-aa),
membrane protein (222-aa), and nucleocapsid protein (419aa) (Phan, 2020)
Figure 4.
Spike glycoprotein (S) consists of S1 and S2 subunits. The S1 subunit contains a
signal peptide, an N-terminal domain (NTD), and RBD, while the S2 subunit
includes the conserved fusion peptide (FP), heptad repeat 1 and 2 (HR1 and
HR2), transmembrane domain (TM), and a cytoplasmic domain (CP) (Dong et
al., 2020, Delmas and Laude, 1990, Xia et al., 2020). Furthermore, the S2
subunit of 2019-nCoV is highly conserved and shares 99% similarity with those
of Bat-SL-CoVZC45, Bat-SL-CoVZC21, and human SARS-CoV (Dong et al.,
2020, Ceraolo and Giorgi, 2020). The E protein helps in virus assembly and
release (DeDiego et al., 2007, Nieto-Torres et al., 2014). The N protein consists
of two domains; they bind to the virus RNA genome via different mechanisms
(Fehr and Perlman, 2015, Chang et al., 2006).

Figure 4. Beta coronaviruses genome organization. The open reading frame
(ORF) (green box), structural proteins including spike (blue box), envelope
(maroon box0, membrane (pink box), and nucleocapsid (cyan box). Accessory
proteins (light gray boxes). The dotted red underlines are the key variations
between SARS-CoV and SARS-CoV2 (Shereen et al., 2020).
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Recent studies declared a bat CoVs sequence, RaTG13, with a 92–96% sequence
identity with the novel virus, confirming that RaTG13 is the closest relative of
the 2019-nCoV and forms distinct lineage from other SARS-CoVs (Paraskevis et
al., 2020, Zhou et al., 2020). This rejects the hypothesis of emergence as a result
of a recombination event which a previous study suggested (Paraskevis et al.,
2020). Despite the high similarities between 2019-nCoV and RaTG13 S, there
are two distinct differences: one is an “RRAR” furin recognition site formed by
an insertion residue in the S1/S2 protease cleavage site in SARS-CoV-2, rather
than the single Arginine in SARS-CoV (Wrapp et al., 2020, Xie and Chen, 2020,
Li et al., 2003b) the other difference is the presence of 29 variant residues
between 2019-nCoV and RaTG13 S, 17 of which mapped to the (RBD) (Wrapp
et al., 2020).
Coronaviruses of animal origin undergo mutations by evolution and genetic
recombination either within the same host species or by transmitting from species
to other, thus resulting in highly pathogenic and deadly viruses to humans (Sabir
et al., 2016, Su et al., 2016). In 2019-nCoV two mutations were identified and
may explain the zoonotic transmission. Genomic alignment of 54 SARS-CoV-2
genomes identified two hotspots of hypervariability at positions 8789
(synonymous variant) and 28,151 (Ser/Leu change), located in the polyprotein
and ORF8 genes respectively (Ceraolo and Giorgi, 2020). There is a single
N501T mutation in SARS-CoV-2’s Spike protein that may have significantly
enhanced its binding affinity for ACE2 (Wan et al., 2020).

Clinical Manifestation
Clinical features of COVID-19 are ranging from an asymptomatic state to acute
respiratory distress syndrome and multi-organ dysfunction (Singhal, 2020). It is
difficult to distinguish COVID-19 from other viral upper respiratory illnesses due
to similar symptoms (Wu and McGoogan, 2020). Fever (78.75%) that does not
alleviate by traditional anti-infective drugs (Huang et al., 2020a), cough
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(63.75%), dyspnea (37.50%), tiredness, sore throat, myalgia (22.50%), and
headache (16.25%) are the most common clinical findings (Wu et al., 2020b,
Jernigan, 2020). In addition to conjunctivitis in some cases (Singhal, 2020).
Many other symptoms have been reported such as loss of tasting and smelling,
increased heart rate (more than 100 bpm), and dehydration (Yang et al., 2020b).
Most patients are asymptomatic or have these mild upper respiratory symptoms
or non-severe pneumonia (Heymann and Shindo, 2020), and have a good
prognosis (Kang et al., 2020). Sever cases (13.8%) have dyspnea, oxygen
saturation less than 93% in ambient air, RR greater than 30 times/min, and
PaO2/FiO2 less than 300 mm Hg (Wu et al., 2020b). Critical cases (4.7%) have
severe complicated pneumonia with acute respiratory distress syndrome (17-29%
of patients) (Huang et al., 2020a), septic shock, and/or multiple organ failure (5%
of cases) (Cascella et al., 2020) and are with poor prognosis (Kang et al., 2020).
A recent study showed that SARS‐CoV‐2 might cause liver damage, renal
damage, and testicular tissue damage (Fan et al., 2020, Chai et al., 2020). While
the overall case fatality rate is estimated to be 6% (WHO, 2020b).
Moreover, lymphocytopenia occurs in 72.3 % of cases (Liu et al., 2020) and
leukopenia in 25% of cases (Sun et al., 2020). Some patients may also
experience confusion, nausea, vomiting, rhinorrhea, and pleurisy (Chen et al.,
2020c), and other complications include acute kidney injury, secondary bacterial
infection, and cardiac injury (Surveillances, 2020). These atypical symptoms are
more likely in the elderly and immunocompromised (WHO, 2020b). Disease in
neonates, infants, and children have been also reported to be significantly milder
than adult (Chavez et al., 2020).
Incubation Period (how long it takes for symptoms to appear)
Symptoms of COVID-19 may appear in as few as 2 days or as long as 14
(estimated ranges vary from 2-10 days, 2-14 days, and 10-14 days, during which
the virus is contagious but the patient does not display any symptom
(asymptomatic transmission). 2-14 days represents the current official estimated
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range for the novel coronavirus COVID-19. However, a case with an incubation
period of 27 days has been reported by Hubei Province local government on Feb.
22 (Reuters, Feb. 22, 2020). Also, a case with an incubation period of 19 days
was observed in a JAMA study of 5 cases published on Feb. 21. (JAMA, Bai Y,
Yao L, Wei T, et al., 2020) An outlier of a 24 days incubation period had been
for the first time observed in a Feb. 9 study (Guan WJ, Ni ZY, Hu Y, et al., 2020)
WHO said at the time that this could reflect a second exposure rather than a long
incubation period and that it wasn't going to change its recommendations. The
period can vary greatly among patients. Mean incubation period observed: 3.0
days (0-24 days range, a study based on 1,324 cases) 5.2 days (4.1-7.0 days
range, based on 425 cases). Mean incubation period observed in travelers from
Wuhan: 6.4 days (range from 2.1 to 11.1 days). The interval from the initiation of
mild symptoms to significant symptom aggravation like breathlessness or ARDS
ranges from one to twenty days, with a median of seven days (Huang et al.,
2020a). However, this interval can extend to forty days depending on the age of
the patient and immune system status (Wang et al., 2020c).
Since the presence of different symptoms that varies among the patients in
addition to the continuous discovery of new clinical features, WHO is
continuously monitoring patients and reporting any new symptoms for a full
understanding of this novel coronavirus (WHO, 2020b). Understanding the
incubation period is very important for health authorities as it allows them to
introduce more effective quarantine systems for people suspected of carrying the
virus, as a way of controlling and hopefully preventing the spread of the virus.

Transmission
α and β types of coronaviruses can infect mammals, while γ and δ types tend to
infect birds (Lau et al., 2010, Yin and Wunderink, 2018). Genome sequencing of
the novel coronavirus has revealed that bats from the Hipposideridae family are
the natural origin of the virus. Palm civets have been suspected to be the
https://digitalcommons.aaru.edu.jo/hujr_a/vol9/iss1/4
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intermediate that disseminates the infection to humans (Yang et al., 2020b).
Some of the earliest infected patients with COVID-19 in Wuhan had a history of
contact with a seafood market that suggests animal-to-person viral transmission
(Lu et al., 2020), then person to person transmission was suggested after the
infection of a new set of patients who did not have a history of exposure to the
mentioned market (Nishiura et al., 2020).
Person To person contact, transmission by touch, and transmission by aerosols
are the major three ways of transmission of COVID-19 coronaviruses in general
(WHO, 2020b). Thus, coronaviruses can be transmitted during coughing or
sneezing by respiratory droplets when propelled up to 3 feet through the air
followed by the droplets deposition on the mucous membranes of the nose,
mouth, or eyes of a close person (Malik et al., 2020) also, the virus can be
transmitted by handshaking and touch of infected surfaces /object (Lu et al.,
2020). Another transmission method is by the transmission of the virus from an
asymptomatic infected person to other contacts which can be referred to as
“hidden transmission” (Chan et al., 2020).
Fecal-oral transmission is suggested as a potential route of transmission after
several studies that reported gastrointestinal symptoms (2-10% of cases) in
infected patients and live virus or viral RNA in feces of some patients (Hindson,
2020, Chen et al., 2020c). The mechanisms by which SARS-CoV-2 affects the
gastrointestinal tract is still unknown, it’s expected to be by use ACE2 as a
receptor for the virus since ACE2 is highly expressed in the GIT (Hindson,
2020). Environmental and enteric studies should be done to inform this route of
transmission and to check the viability of the virus in the feces and viral
concentration in the feces and it correlated with the severity of the infection (Yeo
et al., 2020). Conclusions based on this information, there is evidence that
human-to-human transmission has occurred among close contacts since the
middle of December 2019. Considerable efforts to reduce transmission will be
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required to control outbreaks if similar dynamics apply elsewhere. Measures to
prevent or reduce transmission should be implemented in populations at risk.
Epidemiology
As reported by the WHO Health Emergency Dashboard (April 12, 10 pm GMT),
1,775,206 confirmed cases of COVID-19 (SARS-CoV-2) worldwide and
108,544 (6.18%) confirmed deaths since the beginning of the epidemic, in 213
Countries, areas or territories (WHO, 2020b). In comparison with the previous
outbreak of coronaviruses SARS (2002) infected 8422 people in China and 31
other countries and leads to the death of 919 cases (11%), the number of the
infected persons is very small compared to COVID-19 while the percent of
deaths is still higher (WHO, 2003). By May 28th, 2020, the pandemic cases were
5,868,922 and 360,476 deaths worldwide with a 6.14% mortality rate estimated
by WHO on May 28th, 2020 in 216 Countries. The diseases spread extremely
very fast as by the end of June within only one month, the cases have been nearly
doubled as the coronavirus cases by this time were 10,286,435, deaths 505,252
(8%), and recovered were 5,583,314. The high incidence rate and cases were in
the USA (2,638,386), then Brazil (1,345,470), Russia (641,156), India, UK,
Spain, Peru, Chile, Italy, and Iran respectively. In Palestine by this time, at the
end of June, the reported cases were increased very sharply by about four times,
more than 2,200 cases reported.
A study on 425 infected patients with COVID-19 in china (Feb 2020) showed
that of which 56% of patients were males and the median age was 59 years (Sun
et al., 2020, Li et al., 2020). Another large Chinese study reported that 86.6% of
72,000 patients are of ages ranging from 30-79 with, 81% of them were mild
cases while 2.3% died (Surveillances, 2020) 2.1% of all cases were pediatric
cases (0-19 years old). (Khot and Nadkar, 2020) sever and critical cases represent
only 14.6% (Surveillances, 2020). Severe COVID-19 risk factors are
immunocompromised cases, advanced age, cancer, and chronic illnesses (Khot
and Nadkar, 2020). Patients older than 80 years old presented the highest rate of
https://digitalcommons.aaru.edu.jo/hujr_a/vol9/iss1/4
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fatality (14.8%). Patients with comorbidities such as cardiovascular illnesses had
a fatality rate of 10.5% while those without comorbid conditions had a rate of
fatality less than 1% (Huang et al., 2020a).
The outbreak of the disease globally was continued raising very sharp as by 11 th
July 2020, the coronaviruses cases reported was 12,872,339 and the death cases
were 568,312, the increase rate of the new cases were ~8% and the rate of death
increased by 1.125%; within about two weeks period only, which considered
high rates. The highest incidences were in the USA with 3,356,242 reported
cases; by this time, then Brazil (1,840,812), India (854,480), Russia (727,162),
and Peru (322,710), respectively, as shown in Table-1. In terms of the outbreak
of the disease, the rank of the countries is changing every day, but the USA and
Brazil remain and still rank first and second respectively for some time. In
Palestine by 11th July 2020, the confirmed cases were 6688, and the death cases
were 36, with an increased rate of 304%, which extremely very high and
considered the highest worldwide. The highest cases were in Hebron
Governorate (4620 cases), with about 70% of the total reported cases, as shown
in the geographical location of confirmed cases (Figure 1). The high outbreak of
the disease in this region (Hebron Governorate), as 90% of infections have been
caused by people meeting up with their families or attending wedding parties or
funerals and failing to follow health recommendations and maintain social
distancing according to the Palestinian Ministry of Health officials. The greatest
number of new cases and deaths of COVID-19 being reported by 11th July was in
the USA, Brazil, India, Russia, Peru, Chile, Spain, Mexico, UK, South Africa,
Iran, Pakistan, Italy, and (WHO, 2020b). These growing numbers of cases were
due to the person-to-person transmission that has been reported both in and
outside of China where most initial cases were reported particularly in Hubei
Province (Wang et al., 2020b) Figure 5 & Table-1.
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Figure 5: COVID-19 situation update worldwide, as of 11th July 2020
Association between the ABO Blood Type and COVID-19
Interestingly, a small study conducted on 2,173 patients infected with SARSCoV-2, 206 of them are dead cases, at three hospitals in Wuhan, China, showed
that blood group A was associated with a higher risk for acquiring the COVID-19
compared with non-A blood groups, while blood group O was associated with a
lower risk (Zhao et al., 2020). Previous studies on coronaviruses have shown
results that are consistent with the findings of this study (Cheng et al., 2005a).
This justifies the use of the ABO blood type as a biomarker for differential
susceptibility of COVID-19 (Zhao et al., 2020).
Although the mechanism behind these findings is still unclear, it’s expected that
the lack of anti-A antibodies is the reason behind the increased risk of infection
in persons with A blood group (Trégouët et al., 2009). Thus, the presence of the
anti-A antibodies can protect non-A blood groups by the inhibition of the
interaction between the virus and angiotensin‐converting enzyme 2 (ACE2)
receptor, which was found to be the receptor for SARS‐CoV‐2 (Guillon et al.,
2008, Zhao et al., 2020). This inhibition specifically occurs for the adhesion of S
protein-expressing cells of SARS-CoV to ACE2-expressing cell lines (Guillon et
https://digitalcommons.aaru.edu.jo/hujr_a/vol9/iss1/4
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al., 2008). By the researcher's predictions, SARS-Cov-2 uses ACE2 not only as
its host receptor but also uses ACE2 more efficiently than the SARS-CoV strain
in 2003 (Wan et al., 2020). However, further research and studies are needed to
prove this hypothesis or to explore other mechanisms.
COVID-19 in Pregnancy
Data about pregnancy and neonatal infections are limited, although it’s expected
that pregnant women have a higher risk of severe disease if infected with the
virus due to the pregnancy-related decreased immunity (Schmid et al., 2020),
there is no evidence that pregnancy increases the susceptibility to COVID-19
infection or causes the development of severe pneumonia (Yang et al., 2020a).
Fortunately, unlike the other viruses (except herpes virus) that have
hematogenous transmission from mother to fetus when the virus enters the
placenta from the maternal blood, coronavirus does not follow this mechanism
(Schwartz, 2020). There are a few reported cases of infection of newborn babies
infected by person-to-person contact (Qiao, 2020). Moreover, in a recent study
on six pregnant patients of COVID-19, the study tested samples from cord blood,
amniotic fluid in addition to breastmilk, and neonatal throat swab, all the samples
were negative for SARS-CoV-2 (Chen et al., 2020a). In the same study, the
clinical features of the nine pregnant women with COVID-19 infection were like
the symptoms of non-pregnant infected adults (Huang et al., 2020a).
Animal Hosts of COVID-19
Although researchers are still learning about the novel coronavirus, it’s now
known that it is zoonotic and, in some situations, can spread from people to
animals (Peeri et al., 2020). Scientists are working to establish a potential animal
reservoir for SARS-CoV-2. A recent study in which the susceptibility of animals
in close contact with humans to SARS-CoV-2 had been investigated found that
SARS-CoV-2 replicates poorly in chickens, dogs, ducks, and pigs while cats in
addition to ferrets are permissive to infection (Shi et al 2020). The study
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experimentally confirmed the susceptibility of cats to airborne infections (Shi et
al., 2020). According to reported cases and studies cats can infect each other with
COVID-19 by respiratory droplets. Moreover, the first human-cat transmission
has been reported in Belgium (WHO, 2020b). Besides, two cases of dogs in
Hong Kong tested positive for COVID-19, one of them died. And a tiger tested
positive for the virus after encountering an infected asymptomatic caretaker
(WHO, 2020b).
Diagnosis
Anyone who deals directly with a person who is confirmed to be infected with
the virus must isolate himself from others until the tests are performed. Most
patients with mild cases of COVID-19 have had a fever with and/or symptoms of
acute respiratory illness like cough and difficulty in breathing (CDC, 2020 -d).
Patients with these symptoms must ask the nearest health center specialized for
the examination of COVID-19 to make the test. Patients must wear facemask and
gloves before any interaction with anyone and place in a private room isolated
from another person which is an airborne infection isolated room (CDC, 2020b,
Wax and Christian, 2020). Only health care professionals can enter this room
with fully protected and isolated clothes.
Reverse transcription-polymerase chain reaction (RT-PCR) was used for the
determination of COVID-19. Specific diagnosis is by specific molecular tests on
respiratory samples (throat swab, nasopharyngeal swab, sputum, endotracheal
aspirates, and bronchoalveolar lavage). Also, it can be detected in the stool and
from blood in severe cases (CDC, 2020a). Specimens for virus detection should
reach the laboratory as soon as possible after collection with Correct handling
during transportation. And storage in the lab at 2-8°C (WHO, 2020b). There are
low data available about the sensitivity and specificity for the test, but false
negatives results may be seen in asymptomatic patients and on the patients in the
early stage of the illness so they must be continued in isolation until confirmed
the positive and negative results (CDC, 2020e). Others may have the symptoms
https://digitalcommons.aaru.edu.jo/hujr_a/vol9/iss1/4
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of this virus but with negative results so they don't have the disease (CDC,
2020c).
Inflammatory factors are often increased in severe and critical patients. Patients
in the early stage of the disease have normal or decreased in the total number of
leukocytes in peripheral blood and peripheral blood lymphocytes due to
weakness in the immune system. Some patients show increases in muscle
enzymes, liver enzymes, and myoglobin. Like Troponin which may be elevated
in patients with cardiac involvement so it must be in high consideration for
patients with suspected myocardial infarction or heart failure (Zaman et al.,
2020). Other signs are C-reactive protein (CRP) and erythrocyte sedimentation
rate (ESR) are increased in most patients. In severe cases, patients have higher
plasma levels of IL-2, IL-7, IL-10, G-SCF, IP-10, MCP-1, MIP-1α, TNFα, Ddimer level, and Prothrombin time. In Guan's study, severe cases had more
prominent laboratory abnormalities so 82.1%, 36.2%, and 33.7% of the patients
had lymphopenia, thrombocytopenia, and leukopenia, respectively Compared
with non-severe cases (Guan et al., 2020) Lymphocytopenia can occur in up to
80% of patients, a lymphocyte count <1000 has (Wang et al., 2020a).
Ultrasound may help diagnose coronavirus because it is cheap and reliable and
can be used more than once, but it does not help to see the deeper lesions present
in the lung. However, Patients with COVID-19 have an irregular/thickened
pleural line, scattered/confluent B lines, and consolidation of various sizes and
other abnormalities on the lung in various zones especially in the middle and
outer zones (Zhang et al., 2020). A study of 99 COVID-19 patients found 14%
had mottling and ground-glass opacities, 25% had unilateral pneumonia and 75%
of patients had bilateral pneumonia, on chest X-ray and CT imaging (Chen et al.,
2020c). In another study in Wuhan for a case series of patients with COVID-19,
100% had chest CT findings consistent with pneumonia (Huang et al., 2020a).
Many suspected cases with negative results of COVID-19 have abnormal CT
scans; many of them had positive tests on repeat testing (Huang et al., 2020b).

Published by Arab Journals Platform, 2020

25

ron University Research Journal-A (Natural Sciences) - (???? ????? ?????? ??????- ? (?????? ????????, Vol. 9 [2020], Iss. 1, A
Hejaz A Hatem, et al., A REVIEW ON CORONA VIRUS …., H.U.R.J, Vol. (9), 2020

70

Treatment
As the coronavirus disease 2019 (COVID-19) spreads, efforts are being made to
reduce transmission via standard public health interventions based on isolation of
cases and tracing of contacts. This contributes to reducing the size of the
outbreak but cannot control the outbreak (Hellewell et al., 2020). Other
interventions that were recommended to reduce the outbreak include
strengthening emergency departments, application of strict hygiene measures for
the prevention and control of infection, and avoidance of close contact with
patients suffering from respiratory tract infections (Wu and McGoogan, 2020).
Efforts are being made to find drugs and vaccines that act against SARS-CoV-2
to control the outbreak of the virus. Supportive care is the main strategy for
treatment, preferably with paracetamol for fever. Maintenance of hydration and
nutrition is also required. Up to 76% of patients with COVID-19 require oxygen
therapy. Some patients require endotracheal intubation such as patients with
hypoxemic respiratory patients (Alhazzani et al., 2020). Other patients require
oxygen supplementation to maintain oxygen saturation between 90%-96%
(WHO, 2020a). For patients who do not improve with oxygen therapy, a highflow nasal cannula (HFNC) is recommended (Alhazzani et al., 2020).
Many antivirals are being under clinical trials to find drugs that are effective
against the virus. According to the National Health Commission (NHC) of the
People’s Republic of China for tentative treatment of COVID-19, several
antivirals are recommended including, IFN-α, lopinavir/ritonavir, and ribavirin
treatment of COVID-19. Chloroquine phosphate and arbidol are also
recommended (NHC, 2020).
INF-α is a broad-spectrum antiviral that is usually used to treat hepatitis. It
inhibits the replication of SARS-CoV and MERS-CoV (Falzarano et al., 2013a).
It is also used in combination therapy with other antivirals such as Ribavirin and
lopinavir/ritonavir (Arabi et al., 2020). Lopinavir/ritonavir is a protease inhibitor
that is used for the treatment of HIV (Meynard et al., 2018). Lopinavir works by
https://digitalcommons.aaru.edu.jo/hujr_a/vol9/iss1/4
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inhibiting the decomposition of gag-pol protein, while ritonavir works by
inhibiting the decomposition of gag-pol protein precursor and inhibiting lopinavir
metabolism, thus increasing its concentration (van der Laan et al., 2018). It was
found that lopinavir/ritonavir has anti-SARS-CoV and MERS-CoV activity in
vitro (Chan et al., 2015). In South Korea, an infected patient with COVID-19
received lopinavir/ritonavir. After eight days of admission, symptoms improved
and coronavirus load began to decrease until no longer it’s detectable (Lim et al.,
2020).
Ribavirin is a nucleoside analog with broad-spectrum antiviral activity. It works
by inhibiting the RNA synthesis of viruses. It has been used to treat HCV and
RSV (Brown et al., 2019). Ribavirin is usually used in combination therapy to
treat MERS-CoV and HCoV-OC43. Ribavirin and INF-α combination therapy
are efficient in treating MERS-CoV (Shen et al., 2016). However, ribavirin side
effects like anemia limited its use (Falzarano et al., 2013b). A study compared
ribavirin and lopinavir/ritonavir in treating severe acute respiratory syndrome
(SARS). Patients treated with lopinavir/ritonavir had a lower risk of acute
respiratory distress syndrome and death (Chu et al., 2004). Ribavirin still needs
more studies to determine whether it is effective in treating COVID-19 or not.
Remdesivir is another nucleoside analog with antiviral activity. It has activity
against RNA viruses such as Ebola, Marburg, and Nipa viruses (Lo et al., 2017).
Remdesivir showed activity against MERS-CoV in animal experiments.
Remdesivir reduced the viral load in lung tissue in mice affected with MERSCoV and improved lung function (Sheahan et al., 2020). A randomized, placebocontrolled, double-blind, multicenter, phase III clinical trial is now being made to
study the efficacy and safety of Remdesivir in patients with COVID-19. This
clinical study was launched on February 5, 2020, in China and it’s supposed to
conclude by the end of April. Patients received an initial dose of 200 mg of
Remdesivir and 100 mg subsequent dose for 9 days via IV infusions. The control
group patients received the same dose of placebo. It was found that this dose
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regimen of intravenous remdesivir was adequately tolerated but did not provide
significant clinical or antiviral effects in seriously ill patients with COVID-19.
Studies with larger sample sizes will continue to understand the effect of
remdesivir on COVID-19. Furthermore, strategies to enhance the antiviral
potency of remdesivir (eg, higher-dose regimens, combination with other
antivirals,

or

SARS-CoV-2

neutralizing

antibodies)

and

to

mitigate

immunopathological host responses contributing to COVID-19 severity (eg,
inhibitors of IL-6, IL-1, or TNFα) require rigorous study in patients with severe
COVID-19.
Hydroxychloroquine is a drug used to treat malaria and autoimmune diseases
such as lupus and rheumatoid arthritis. Hydroxychloroquine has been
demonstrated to affect SARS-CoV-2 (Yao et al., 2020). A recent study showed
the efficacy of hydroxychloroquine in reducing viral nasopharyngeal carriage of
SARS-CoV-2 in COVID-19 patients in an average of three to six days only
(Gautret et al., 2020). Azithromycin has been recommended to use with
hydroxychloroquine to give a synergistic effect in treating COVID-19.
Azithromycin has been shown to prevent severe respiratory tract infections and
has activity against Ebola and Zika viruses (Bosseboeuf et al., 2018).
Arbidol is an antiviral used to treat the influenza virus. A study found that
Arbidol can inhibit SARS-CoV-2 in vitro. Another antiviral that may have antiSARS-CoV-2 activity is Favipiravir. Favipiravir is an RNA-dependent RNA
polymerase (RdRP) inhibitor. It has anti-influenza activity and it can block the
replication of filo-, alpha-, arena-, and other RNA viruses (Delang et al., 2018).
When entering the cells, Favipiravir is converted to its active form FavipiravirRTP and it is recognized as a substrate by viral RNA polymerase, thus inhibiting
its activity (Furuta et al., 2017). Therefore, Favipiravir may be effective against
SARS-CoV-2 (Table 2).
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Table 1. Antivirals included in the NHC guidelines (version 6)
Drug

Dosage

Method of
Administration
Vapor inhalation

Duration of
Treatment
No more than
10 days

IFN-α

5 million U or equivalent dose
each time, 2 times/day

Lopinavir/
Ritonavir

200 mg/50 mg/capsule, 2
capsules each time, 2 times/day

Oral

No more than
10 days

Ribavirin

500 mg each time, 2 to 3
times/day in combination with
IFN-α or lopinavir/ritonavir

Intravenous
infusion

No more than
10 days

Chloroquin
e phosphate

500 mg (300 mg for
chloroquine) each time, 2
times/day

Oral

No more than
10 days

Arbidol

200 mg each time, 3 times/day

Oral

No more than
10 days

Convalescent plasma therapy is another treatment that is now under investigation
for its efficacy against the SARS-CoV-2 virus. The use of convalescent plasma
was recommended as an empirical therapy during the outbreak of the Ebola
virus. It was also recommended as a protocol for the treatment of MERS-CoV in
2015 (Chen et al., 2020b). Viremia usually peaks in the first week and a potential
immune response is likely to be developed in the second weak where serum
cytokines increase above the normal range (Cheng et al., 2005a). Some studies
found that convalescent plasma might suppress viremia (Schoofs et al., 2016).
Another study found that convalescent plasma could reduce serum cytokine
response (Hung et al., 2011). This indicates that convalescent therapy is only
effective in the early stages of the disease (Cheng et al., 2005b). The therapeutic
effect of convalescent plasma is dependent upon the level of SARS-CoV-2
neutralizing antibody titer (NAT). IgG immunoglobulin began to increase in the
third week of onset, and peaks at the twelfth weak (Li et al., 2003a). One study
found that convalescent plasma with NAT ≥ 1:16 reduced the mortality of
influenza (Hung et al., 2011). Thus, it is better to take plasma from patients who
have recovered and are at week 12 of onset with a NAT level of ≥ 1:16.
Furthermore, it also needs more studies to prove its effectiveness.
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Prevention
There is no proven treatment for coronavirus, so prevention is very important.
Because of the characteristics of this virus, as it has a long incubation period, the
infection can be transmitted to many people before symptoms appear, so
preventive measures are very necessary.
The greatest danger is the transmission of the virus to a healthcare worker as the
virus has passed on to many of them, however, it is very important to follow a
basic protocol to protect them and prevent the transmission of the disease to them
and others by them (Chang et al., 2020). Those who deal with patients directly
are isolated from others and do not deal with ordinary patients. The rooms and
surfaces and equipment should undergo regular decontamination.
To reduce the spread of the disease in geographical areas, each country
quarantines travelers and people who dealt with the injured for 14 days to ensure
that they are free of the virus and prevent its spread (Gostic et al., 2015).
As for society, the best ways to prevent coronavirus and other viruses are
necessary to move away from crowded places, leave a safe distance between
others and follow a healthy lifestyle that is mainly based on maintaining personal
hygiene, eating healthy foods, good ventilation, sunlight penetration on all
surfaces, adequate rest, using health masks and using sterilizers on an ongoing
every 15-20min (Gostic et al., 2015, Simpson et al., 2015, Yoshikawa and High,
2001). People who already have a vitamin C deficiency are more likely and at
risk to become infected with the virus (Nonnecke et al., 2014). So vitamin C
supplementation is very important for prevention according to many studies
(Hemilä, 1997). Every year an estimated 290,000 to 650,000 people die in the
world due to complications from seasonal influenza (flu) viruses. There are about
795 to 1,781 deaths per day due to the seasonal flu. SARS (November 2002 to
July 2003). The coronavirus that originated from Beijing, China, spread to
different countries and resulted in more than ten and a half million people
infected with more than half-million deaths (fatality rate of 8%, by end of June
https://digitalcommons.aaru.edu.jo/hujr_a/vol9/iss1/4
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2020). Considering that SARS ended up infecting 5,237 people in mainland
China, Wuhan Coronavirus surpassed SARS on January 29, 2020, when Chinese
officials confirmed 5,974 cases of the novel coronavirus (2019-nCoV). One day
later, on January 30, 2020, the novel coronavirus cases surpassed even the 8,096
cases worldwide which were the final SARS count in 2003, and now by the end
of June 2020 coronavirus exceed SARS by millions as mentioned.
Conclusion
Coronavirus disease 2019 (COVID-19) has affected more than twelve million
people worldwide until today in 216 countries. Symptoms of this virus may vary
from mild symptoms such as fever and cough to severe symptoms in some
patients such as a proinflammatory and hypercoagulable state, in addition to noncardiac pneumonia, multi-organ failure, and ARDS. Supportive treatment is still
the main strategy in treating this disease since there is no evidence that current
medicine can prevent or cure the infection resulting from coronavirus. Isolating
patients and other preventive measures are now the way in reducing the outbreak
of this virus infection.
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